English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Psoriasis is a chronic inflammatory skin disorder with a significant disease burden. While numerous treatments exist, development of effective and affordable therapies offering good patient outcomes remains desirable. A mixture of fumaric acid esters (FAE) is commonly prescribed for oral treatment of moderate-to-severe plaque psoriasis in Germany. In other European countries (UK, Ireland, Italy, and the Netherlands, among others), FAE have been imported or compounded by local pharmacies. Current international guidelines recommend FAE for the short- and long-term management of psoriasis. Although the original formulation (Fumaderm ) contains a mixture of FAE, the main active ingredient is dimethylfumarate (DMF), an anti-inflammatory and immune-modulating agent with proven efficacy in psoriasis. The monoethylfumarate salts within the FAE formulation have shown much lower biological activity both in vitro and in vivo. This article is protected by copyright. All rights reserved.

Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis